Cargando…
A novel immune-related model to predict prognosis and responsiveness to checkpoint and angiogenesis blockade therapy in advanced renal cancer
BACKGROUND: Immune checkpoint blockade (ICB) and anti-angiogenic drug combination has prolonged the survival of patients with advanced renal cell carcinoma (RCC). However, not all patients receive clinical benefits from this intervention. In this study, we aimed to establish a promising immune-relat...
Autores principales: | Chen, Peng, Bi, Feng, Tan, Weili, Jian, Lian, Yu, Xiaoping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043594/ https://www.ncbi.nlm.nih.gov/pubmed/36998443 http://dx.doi.org/10.3389/fonc.2023.1127448 |
Ejemplares similares
-
Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade
por: Lavoie, Jean-Michel, et al.
Publicado: (2022) -
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
por: Swart, Maarten, et al.
Publicado: (2016) -
Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
por: Lei, Yanna, et al.
Publicado: (2021) -
Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data
por: Song, Zhuo, et al.
Publicado: (2022) -
Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade
por: Olsen, T. Anders, et al.
Publicado: (2021)